




- 51 year old Chinese female was diagnosed to have right breast invasive cancer.
- Neoadjuvant chemotherapy was administered.
- A simple mastectomy with axillary clearance followed.
- A solid-mucinous tumour measuring up to 3.5cm was noted straddling the upper breast quadrants.
















































EMA



Invasive micropapillary and mucinous carcinoma.

Invasive mucinous carcinoma

- >90% of the tumour shows mucinous morphology.
- Mixed ductal and mucinous if mucinous features in 50% to 90% of the tumour.
- Incidence ranges from 0.8-6%.
- Postmenopausal women, mean age 59-71 years.

- 1.2-2.3% of all invasive breast carcinomas in the pure form.
- More often seen accompanying infiltrative ductal carcinoma, 7%.
- Age range: 28-92 years; mean 52-58 years.
- High incidence of lymphovascular invasion and axillary nodal metastases.
- Minor component also important.

Grossly:

- Average tumour size 2-4cm (range 0.1-10cm).
- 23% reported to be 1cm or less.
- Non-specific appearance of gray-white, stellate and firm cut surface.

Microscopically:

- Solid/tubular epithelial nests within clear spaces.
- Spaces due to artefactual shrinkage, not seen on frozen sections.
- Lack of true fibrovascular cores.
- Commonly constitutes < 20% tumour when seen accompanying infiltrative ductal carcinoma.
- Histologic grade 3 (58-82%).
- Lymphovascular invasion (63-76%).
- Multifocality (31%).
- Lymph node positivity (69-95%)
- Small tumours (T1a and T1b) are also associated with a high incidence of axillary nodal metastases (64% and 75% respectively)

• Immunohistochemistry:

- EMA shows characteristic "inside-out" pattern.
- ER positivity in 61-90%, PR positivity 61-70%.
- cerbB2 positivity up to 54%.

Molecular studies:

- Comparative genomic hybridization (CGH) showed average of 7.4 chromosomal alterations per case (lower than tumours of no special type).
- 8p loss with 88% showing 8q gains.

• Prognosis:

- Local recurrence rate of 22% (vs 12% for ductal NOS).
- Distant metastatic rate similar to ductal NOS (25% vs 23%).
- Mortality within 9 years of 28% vs 18% (ductal NOS).
- 46% mortality with a follow-up of 143 months.
- 42-52% of cases present with 4 or more positive lymph nodes.
- Overall survival similar to other subtypes when matched stage for stage.

Learning points

- Postchemotherapy changes represented by stromal fibrosis and patchy oedema.
- Differences between invasive micropapillary carcinoma and mucinous carcinoma.